Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Yellow Fever Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Yellow Fever Overview | 8 | 1 |
| Pipeline Products for Yellow Fever Comparative Analysis | 9 | 1 |
| Yellow Fever Therapeutics under Development by Companies | 10 | 1 |
| Yellow Fever Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Yellow Fever Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Yellow Fever Products under Development by Companies | 14 | 1 |
| Yellow Fever Products under Investigation by Universities/Institutes | 15 | 1 |
| Yellow Fever Companies Involved in Therapeutics Development | 16 | 10 |
| Arno Therapeutics, Inc. | 16 | 1 |
| Bavarian Nordic A/S | 17 | 1 |
| BioCryst Pharmaceuticals, Inc. | 18 | 1 |
| Ennaid Therapeutics, LLC | 19 | 1 |
| iBio, Inc. | 20 | 1 |
| Johnson &Johnson | 21 | 1 |
| NewLink Genetics Corporation | 22 | 1 |
| Panacea Biotec Limited | 23 | 1 |
| Sihuan Pharmaceutical Holdings Group Ltd. | 24 | 1 |
| Valneva SE | 25 | 1 |
| Yellow Fever Therapeutics Assessment | 26 | 10 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Combination Products | 27 | 1 |
| Assessment by Target | 28 | 2 |
| Assessment by Mechanism of Action | 30 | 2 |
| Assessment by Route of Administration | 32 | 2 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 25 |
| (arenavirus + yellow fever) vaccine Drug Profile | 36 | 1 |
| AR-12 Drug Profile | 37 | 3 |
| BCX-4430 Drug Profile | 40 | 3 |
| DEF-201 Drug Profile | 43 | 2 |
| FDX-000 Drug Profile | 45 | 1 |
| JK-05 Drug Profile | 46 | 1 |
| RKP-00156 Drug Profile | 47 | 1 |
| Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections Drug Profile | 48 | 1 |
| Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections Drug Profile | 49 | 1 |
| Synthetic Peptides for Yellow Fever Drug Profile | 50 | 1 |
| XRX-001 Drug Profile | 51 | 1 |
| yellow fever [strain YF17D] vaccine Drug Profile | 52 | 1 |
| yellow fever vaccine Drug Profile | 53 | 1 |
| yellow fever vaccine Drug Profile | 54 | 1 |
| yellow fever vaccine Drug Profile | 55 | 1 |
| yellow fever vaccine Drug Profile | 56 | 1 |
| yellow fever vaccine Drug Profile | 57 | 1 |
| yellow fever vaccine Drug Profile | 58 | 1 |
| yellow fever vaccine Drug Profile | 59 | 1 |
| yellow fever vaccine Drug Profile | 60 | 1 |
| Yellow Fever Dormant Projects | 61 | 1 |
| Yellow Fever Product Development Milestones | 62 | 3 |
| Featured News &Press Releases | 62 | 1 |
| Jul 27, 2016: Bavarian Nordic Announces Initiation of NIH Sponsored Phase 1 Trial of MVA-BN-based Yellow Fever Vaccine | 62 | 1 |
| Jul 27, 2016: NIH launches early-stage yellow fever vaccine trial | 62 | 1 |
| Apr 07, 2011: Xcellerex Announces Positive Results From Phase I Clinical Trial Of XRX-001 | 63 | 2 |
| Appendix | 65 | 2 |
| Methodology | 65 | 1 |
| Coverage | 65 | 1 |
| Secondary Research | 65 | 1 |
| Primary Research | 65 | 1 |
| Expert Panel Validation | 65 | 1 |
| Contact Us | 65 | 1 |
| Disclaimer | 66 | 1 |